Compare ARK Genomic Revolution ETF (ARKG) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Kimberly Clark Corp — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Kimberly Clark Corp trades at $112.58 (market cap $37.31B). The key difference: Kimberly Clark Corp pays a 4.55% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Kimberly Clark Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | KMB | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $136.77 |
52-Week Low | $23.09 | $93.05 |
Market Cap | — | $37.31B |
Enterprise Value | — | $43.86B |
Dividend Yield | — | 4.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Kimberly-Clark (KMB) trades at $112.41, up 2.26% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company maintains strong profitability with a 12.8% net income margin and a high ROE of 146.29%, though revenue declined to $16.45B in 2025. Recent news highlights its dividend reliability and upcoming Q2 2026 results announcement on August 4, 2026.
KMB offers a stable dividend yield and defensive appeal, but faces headwinds from revenue pressure and high valuation multiples. Analyst consensus is mixed with a $109 price target below the current price, suggesting cautious optimism. Key risks include consumer sentiment impacts and input cost inflation, requiring monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
